Neurological Institute Outcomes
Headache
Anti-Calcitonin Gene-Related Peptide Antibody Therapy for Migraine
Cleveland Clinic’s Section of Headache and Facial Pain, within the Center for Neurological Restoration, is among the largest and most comprehensive centers in the world dedicated to managing and treating headache and facial pain syndrome.
Outcomes Following Treatment With CGRP Monoclonal Antibodies (N = 64)
2022
CGRP = Calcitonin Gene-Related Peptide, GAD-7 = Generalized Anxiety Disorder Questionnaire, HIT-6 = Headache Impact Test, PHQ-9 = Patient Health Questionnaire, PROMIS = Patient Reported Outcome Measurement Information System.
Treatments targeting calcitonin gene-related peptide (CGRP) were approved by the FDA in 2018 and remain one of the most innovative treatments for patients with migraine. Cleveland Clinic's Headache Center has been at the forefront in prescribing these treatments and evaluating outcomes. In 2022, 64 headache patients completed at least 1 follow-up questionnaire following initiation of CGRP treatment in 2021 or 2022. Ninety-six percent of patients had improved or stable headache impact scores.¹ PROMIS global health,² depression,³ and anxiety⁴ were stable or improved in 78% of patients or more.